The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
MicroRNA-122 Inhibits Tumorigenic Properties of Hepatocellular Carcinoma Cells and Sensitizes These Cells to Sorafenib
Open accessAbstract
MicroRNAs are negative regulators of protein coding genes. The liver-specific microRNA-122 (miR-122) is frequently suppressed in primary hepatocellular carcinomas (HCCs). In situ hybridization demonstrated that miR-122 is abundantly expressed in hepatocytes but barely detectable in primary human HCCs. Ectopic expression of miR-122 in nonexpressing HepG2, Hep3B, and SK-Hep-1 cells reversed their tumorigenic properties such as growth, replication potential, clonogenic survival, anchorage-independent growth, migration, invasion, and tumor formation in nude mice. Further, miR-122-expressing HCC cells retained an epithelial phenotype that correlated with reduced Vimentin expression. ADAM10 (a distintegrin and metalloprotease family 10), serum response factor (SRF), and insulin-like growth factor 1 receptor (Igf1R) that promote tumorigenesis were validated as targets of miR-122 and were repressed by the microRNA. Conversely, depletion of the endogenous miR-122 in Huh-7 cells facilitated their tumorigenic properties with concomitant up-regulation of these targets. Expression of SRF or Igf1R partially reversed tumor suppressor function of miR-122. Further, miR-122 impeded angiogenic properties of endothelial cells in vitro. Notably, ADAM10, SRF, and Igf1R were up-regulated in primary human HCCs compared with the matching liver tissue. Co-labeling studies demonstrated exclusive localization of miR-122 in the benign livers, whereas SRF predominantly expressed in HCC. More importantly, growth and clonogenic survival of miR-122-expressing HCC cells were significantly reduced upon treatment with sorafenib, a multi-kinase inhibitor clinically effective against HCC. Collectively, these results suggest that the loss of multifunctional miR-122 contributes to the malignant phenotype of HCC cells, and miR-122 mimetic alone or in combination with anticancer drugs can be a promising therapeutic regimen against liver cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
6 retracted
RETRACTED: Downregulation of miR‐122 in the rodent and human hepatocellular carcinomas
Kutay, H., Bai, S., Datta, J., Motiwala, T., Pogribny, I., Frankel, W., Jacob, S. T., & Ghoshal, K. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20982 · Cited by 608
Self-citationRetractedDatta, J., Kutay, H., Nasser, M. W., Nuovo, G. J., Wang, B., Majumder, S., Liu, C.-G., Volinia, S., Croce, C. M., Schmittgen, T. D., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6655 · Cited by 438
Self-citationRetractedGhoshal, K., Datta, J., Majumder, S., Bai, S., Kutay, H., Motiwala, T., & Jacob, S. T. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.11.4727-4741.2005 · Cited by 431
Self-citationRetractedNasser, M. W., Datta, J., Nuovo, G., Kutay, H., Motiwala, T., Majumder, S., Wang, B., Suster, S., Jacob, S. T., & Ghoshal, K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804788200 · Cited by 360
Self-citationRetractedMotiwala, T., Kutay, H., Ghoshal, K., Bai, S., Seimiya, H., Tsuruo, T., Suster, S. M., Morrison, C., & Jacob, S. T. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405451101 · Cited by 111
Self-citationRetractedPTPROt Inactivates the Oncogenic Fusion Protein BCR/ABL and Suppresses Transformation of K562 Cells
Motiwala, T., Majumder, S., Ghoshal, K., Kutay, H., Datta, J., Roy, S., Lucas, D. M., & Jacob, S. T. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802840200 · Cited by 31
Self-citationRetractedMicroRNAs: Target Recognition and Regulatory Functions
Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.01.002 · Cited by 20,068
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005) · Cell · doi:10.1016/j.cell.2004.12.035 · Cited by 11,855
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1997 · Cited by 7,590
Cited by
Nagy, Á., Lánczky, A., Menyhárt, O., & Győrffy, B. (2018) · Scientific Reports · doi:10.1038/s41598-018-27521-y · Cited by 1,319
MicroRNAs in metabolism and metabolic disorders
Rottiers, V., & Näär, A. M. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3313 · Cited by 1,156
MicroRNAs in Development and Disease
Sayed, D., & Abdellatif, M. (2011) · Physiological Reviews · doi:10.1152/physrev.00006.2010 · Cited by 1,078
MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy
Kasinski, A. L., & Slack, F. J. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3166 · Cited by 936
Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver
Hsu, S.-H., Wang, B., Kota, J., Yu, J., Costinean, S., Kutay, H., Yu, L., Bai, S., La Perle, K., Chivukula, R. R., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63539 · Cited by 774
Self-citationRapid electronic detection of probe-specific microRNAs using thin nanopore sensors
Wanunu, M., Dadosh, T., Ray, V., Jin, J., McReynolds, L., & Drndić, M. (2010) · Nature Nanotechnology · doi:10.1038/nnano.2010.202 · Cited by 736
Lou, G., Song, X., Yang, F., Wu, S., Wang, J., Chen, Z., & Liu, Y. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0220-7 · Cited by 651
miR-122 – A key factor and therapeutic target in liver disease
Bandiera, S., Pfeffer, S., Baumert, T. F., & Zeisel, M. B. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.10.004 · Cited by 629
Xu, J., Wu, C., Che, X., Wang, L., Yu, D., Zhang, T., Huang, L., Li, H., Tan, W., Wang, C., et al. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20712 · Cited by 567
Liver-specific microRNA-122: Biogenesis and function
Jopling, C. (2012) · RNA Biology · doi:10.4161/rna.18827 · Cited by 415
MicroRNAs: New Tools for Diagnosis, Prognosis, and Therapy in Hepatocellular Carcinoma?
Giordano, S., & Columbano, A. (2013) · Hepatology · doi:10.1002/hep.26095 · Cited by 354
Wei, L., Wang, X., Lv, L., Liu, J., Xing, H., Song, Y., Xie, M., Lei, T., Zhang, N., & Yang, M. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1086-z · Cited by 339
Treating cancer with microRNA replacement therapy: A literature review
Hosseinahli, N., Aghapour, M., Duijf, P. H. G., & Baradaran, B. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26514 · Cited by 305
MicroRNAs as Potential Signatures of Environmental Exposure or Effect: A Systematic Review
Vrijens, K., Bollati, V., & Nawrot, T. S. (2015) · Environmental Health Perspectives · doi:10.1289/ehp.1408459 · Cited by 304
Recent advances in hepatocellular carcinoma therapy
Dutta, R., & Mahato, R. I. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.010 · Cited by 280
van der Ree, M. H., de Vree, J. M., Stelma, F., Willemse, S., van der Valk, M., Rietdijk, S., Molenkamp, R., Schinkel, J., van Nuenen, A. C., Beuers, U., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31715-9 · Cited by 271
Xu, H., He, J.-H., Xiao, Z.-D., Zhang, Q.-Q., Chen, Y.-Q., Zhou, H., & Qu, L.-H. (2010) · Hepatology · doi:10.1002/hep.23818 · Cited by 270
Young, D. D., Connelly, C. M., Grohmann, C., & Deiters, A. (2010) · Journal of the American Chemical Society · doi:10.1021/ja910275u · Cited by 260
Wang, S., Qiu, L., Yan, X., Jin, W., Wang, Y., Chen, L., Wu, E., Ye, X., Gao, G. F., Wang, F., et al. (2012) · Hepatology · doi:10.1002/hep.24809 · Cited by 259
MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma
Wang, W., Zhao, L.-J., Tan, Y.-X., Ren, H., & Qi, Z.-T. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs113 · Cited by 182
Wang, D., Sun, X., Wei, Y., Liang, H., Yuan, M., Jin, F., Chen, X., Liu, Y., Zhang, C.-Y., Li, L., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1254 · Cited by 82
Luna, J. M., Barajas, J. M., Teng, K.-Y., Sun, H.-L., Moore, M. J., Rice, C. M., Darnell, R. B., & Ghoshal, K. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.06.025 · Cited by 80
Self-citationmiR-122 Inhibits Hepatocarcinoma Cell Progression by Targeting LMNB2
Li, X.-N., Yang, H., & Yang, T. (2020) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504019x15615433287579 · Cited by 34
Retracted
Metadata
- Authors
- Bai, S., Nasser, M. W., Wang, B., Hsu, S.-H., Datta, J., Kutay, H., Yadav, A., Nuovo, G., Kumar, P., & Ghoshal, K.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2009-11
- Volume
- 284
- Issue
- 46
- Pages
- 32015-32027
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2073391234
- Cited by
- 477
- References
- 45
- FWCI
- 11.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.